REG - AstraZeneca PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

16/12/2016 13:00

RNS Number : 0977S
AstraZeneca PLC
16 December 2016
16 December 2016 13:00
Transaction by a Person Discharging Managerial Responsibilities
Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation
On 16 December 2016, Pascal Soriot, a Director of the Company, notified us that, on 16 December 2016, he ceased to be beneficially interested in 59,951 AstraZeneca PLC Ordinary Shares of $0.25 each as a result of a gift of those shares to family members for nil consideration.
The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 
Details of the person discharging managerial responsibilities / person closely associated 
a) 
Name 
Pascal Soriot
2 
Reason for the notification 
a) 
Position/status 
Chief Executive Officer
b) 
Initial notification /Amendment 
Initial notification
3 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
a) 
Name 
AstraZeneca PLC
b) 
LEI 
Not applicable
4 
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 
a) 
Description of the financial instrument, type of instrument 
Identification code 
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
b) 
Nature of the transaction 
Gift of shares to family members for nil consideration
c) 
Price(s) and volume(s) 
Price(s)
Volume(s)
0
59,951
d) 
Aggregated information 
- Aggregated volume 
- Price 
Not applicable - single transaction
e) 
Date of the transaction 
16 December 2016
f) 
Place of the transaction 
London
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Neil Burrows
UK/Global
+44 203 749 5637
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, neuroscience & infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHUNVARNBAUAAA